Gary W. Pace, Director at Cardiff Oncology, Inc. (CRDF), bought 30,000 shares at $6.75 ($203K) on 2021-09-21, disclosed to the SEC on 2021-09-22.
Open-market purchase of $202k CRDF by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| Filing → |
| CRDF | BUY | 2025-07-31 | $711K | — | Filing → |
| CRDF | BUY | 2024-12-12 | $940K | — | Filing → |
| PCRX | SELL | 2024-03-08 | $4.5M | — | Filing → |